Compare FG & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FG | RCUS |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United States |
| Employees | 1338 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | N/A | 2018 |
| Metric | FG | RCUS |
|---|---|---|
| Price | $24.51 | $21.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $35.00 | $29.20 |
| AVG Volume (30 Days) | 578.2K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $7.94 | N/A |
| Revenue Next Year | $5.51 | $70.88 |
| P/E Ratio | $8.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.57 | $6.79 |
| 52 Week High | $37.19 | $26.40 |
| Indicator | FG | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 47.82 |
| Support Level | $20.97 | $20.35 |
| Resistance Level | $29.63 | $21.55 |
| Average True Range (ATR) | 0.76 | 1.14 |
| MACD | 0.49 | -0.24 |
| Stochastic Oscillator | 92.36 | 25.36 |
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.